Activation of ERBB4 in glioblastoma can contribute to increased tumorigenicity and influence therapeutic response

Cancers

Volumn 10, Issue 8, 2018, Pages

  Donoghue, Jacqueline F ^a   Kerr, Lauren T ^a,b   Alexander, Naomi W ^c   Greenall, Sameer A ^a,b   Longano, Anthony B ^d   Gottardo, Nicholas G ^c   Wang, Rong ^e   Tabar, Viviane ^e   Adams, Timothy E ^f   Mischel, Paul S ^g   Johns, Terrance G ^a,b,c  

^a HUDSON INSTITUTE OF MEDICAL RESEARCH   (Australia)

^b MONASH UNIVERSITY   (Australia)

^c UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

^d MONASH MEDICAL CENTRE   (Australia)

^e MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^f CSIRO   (Australia)

^g UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

EGFR; ERBB4; GBM; Prognosis; Therapy

Indexed keywords

DACOMITINIB; EPIDERMAL GROWTH FACTOR RECEPTOR 4; MESSENGER RNA; PANITUMUMAB;

ANGIOGENESIS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER PROGNOSIS; CANCER SURVIVAL; CARCINOGENICITY; CELL ACTIVATION; CELL COUNT; CELL GROWTH; CELL PROLIFERATION; CONCENTRATION RESPONSE; CROSS REACTION; DISEASE MARKER; DRUG EFFICACY; DRUG RESPONSE; DRUG TOLERABILITY; GLIOBLASTOMA; MOUSE; NERVE CELL; NONHUMAN; OVERALL SURVIVAL; PROTEIN CLEAVAGE; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN INTERACTION; PROTEIN LOCALIZATION; PROTEIN PHOSPHORYLATION; SURVIVAL RATE; UPREGULATION;

EID: 85051109490     PISSN: None     EISSN: 20726694     Source Type: Journal    
DOI: 10.3390/cancers10080243     Document Type: Article

References (51)

1. Maher, E.A.; Furnari, F.B.; Bachoo, R.M.; Rowitch, D.H.; Louis, D.N.; Cavenee, W.K.; DePinho, R.A. Malignant glioma: Genetics and biology of a grave matter. Genes Dev. 2001, 15, 1311–1333. [CrossRef] [PubMed]
2. Wen, P.Y.; Kesari, S. Malignant gliomas in adults. N. Engl. J. Med. 2008, 359, 492–507. [CrossRef] [PubMed]
3. Inda, M.M.; Bonavia, R.; Mukasa, A.; Narita, Y.; Sah, D.W.; Vandenberg, S.; Brennan, C.; Johns, T.G.; Bachoo, R.; Hadwiger, P.; et al. Tumor heterogeneity is an active process maintained by a mutant EGFR-induced cytokine circuit in glioblastoma. Genes Dev. 2010, 24, 1731–1745. [CrossRef] [PubMed]
4. Van den Bent, M.J.; Brandes, A.A.; Rampling, R.; Kouwenhoven, M.C.; Kros, J.M.; Carpentier, A.F.; Clement, P.M.; Frenay, M.; Campone, M.; Baurain, J.F.; et al. Randomized phase II trial of erlotinib versus temozolomide or carmustine in recurrent glioblastoma: EORTC brain tumor group study 26034. J. Clin. Oncol. 2009, 27, 1268–1274. [CrossRef] [PubMed]
5. Brown, P.D.; Krishnan, S.; Sarkaria, J.N.; Wu, W.; Jaeckle, K.A.; Uhm, J.H.; Geoffroy, F.J.; Arusell, R.; Kitange, G.; Jenkins, R.B.; et al. Phase I/II trial of erlotinib and temozolomide with radiation therapy in the treatment of newly diagnosed glioblastoma multiforme: North central cancer treatment group study N0177. J. Clin. Oncol. 2008, 26, 5603–5609. [CrossRef] [PubMed]
6. Shinojima, N.; Tada, K.; Shiraishi, S.; Kamiryo, T.; Kochi, M.; Nakamura, H.; Makino, K.; Saya, H.; Hirano, H.; Kuratsu, J.; et al. Prognostic value of epidermal growth factor receptor in patients with glioblastoma multiforme. Cancer Res. 2003, 63, 6962–6970. [PubMed]
7. Hatanpaa, K.J.; Burma, S.; Zhao, D.; Habib, A.A. Epidermal growth factor receptor in glioma: Signal transduction, neuropathology, imaging, and radioresistance. Neoplasia 2010, 12, 675–684. [CrossRef] [PubMed]
8. Heimberger, A.B.; Hlatky, R.; Suki, D.; Yang, D.; Weinberg, J.; Gilbert, M.; Sawaya, R.; Aldape, K. Prognostic effect of epidermal growth factor receptor and EGFRVIII in glioblastoma multiforme patients. Clin. Cancer Res. 2005, 11, 1462–1466. [CrossRef] [PubMed]
9. Benito, R.; Gil-Benso, R.; Quilis, V.; Perez, M.; Gregori-Romero, M.; Roldan, P.; Gonzalez-Darder, J.; Cerda-Nicolas, M.; Lopez-Gines, C. Primary glioblastomas with and without EGFR amplification: Relationship to genetic alterations and clinicopathological features. Neuropathology 2010, 30, 392–400. [CrossRef] [PubMed]
10. Andersson, U.; Guo, D.; Malmer, B.; Bergenheim, A.T.; Brannstrom, T.; Hedman, H.; Henriksson, R. Epidermal growth factor receptor family (EGFR, ERBB2–4) in gliomas and meningiomas. Acta Neuropathol. 2004, 108, 135–142. [CrossRef] [PubMed]
11. Duhem-Tonnelle, V.; Bieche, I.; Vacher, S.; Loyens, A.; Maurage, C.A.; Collier, F.; Baroncini, M.; Blond, S.; Prevot, V.; Sharif, A. Differential distribution of ERBB receptors in human glioblastoma multiforme: Expression of ERBB3 in CD133-positive putative cancer stem cells. J. Neuropathol. Exp. Neurol. 2010, 69, 606–622. [CrossRef] [PubMed]
12. Stommel, J.M.; Kimmelman, A.C.; Ying, H.; Nabioullin, R.; Ponugoti, A.H.; Wiedemeyer, R.; Stegh, A.H.; Bradner, J.E.; Ligon, K.L.; Brennan, C.; et al. Coactivation of receptor tyrosine kinases affects the response of tumor cells to targeted therapies. Science 2007, 318, 287–290. [CrossRef] [PubMed]
13. Gassmann, M.; Casagranda, F.; Orioli, D.; Simon, H.; Lai, C.; Klein, R.; Lemke, G. Aberrant neural and cardiac development in mice lacking the ERBB4 neuregulin receptor. Nature 1995, 378, 390–394. [CrossRef] [PubMed]
14. Srinivasan, R.; Poulsom, R.; Hurst, H.C.; Gullick, W.J. Expression of the c-ERBB-4/HER4 protein and mRNA in normal human fetal and adult tissues and in a survey of nine solid tumour types. J. Pathol. 1998, 185, 236–245. [CrossRef]
15. Law, A. Schizophrenia, IV: Neuregulin-1 in the human brain. Am. J. Psychiatry 2003, 160, 1392. [CrossRef] [PubMed]
16. Gilbertson, R.; Hernan, R.; Pietsch, T.; Pinto, L.; Scotting, P.; Allibone, R.; Ellison, D.; Perry, R.; Pearson, A.; Lunec, J. Novel ERBB4 juxtamembrane splice variants are frequently expressed in childhood medulloblastoma. Genes Chromosomes Cancer 2001, 31, 288–294. [CrossRef] [PubMed]
17. Gilbertson, R.J.; Bentley, L.; Hernan, R.; Junttila, T.T.; Frank, A.J.; Haapasalo, H.; Connelly, M.; Wetmore, C.; Curran, T.; Elenius, K.; et al. ERBB receptor signaling promotes ependymoma cell proliferation and represents a potential novel therapeutic target for this disease. Clin. Cancer Res. 2002, 8, 3054–3064. [PubMed]
18. Plowman, G.D.; Culouscou, J.M.; Whitney, G.S.; Green, J.M.; Carlton, G.W.; Foy, L.; Neubauer, M.G.; Shoyab, M. Ligand-specific activation of HER4/p180ERBB4, a fourth member of the epidermal growth factor receptor family. Proc. Natl. Acad. Sci. USA 1993, 90, 1746–1750. [CrossRef] [PubMed]
19. Junttila, T.T.; Sundvall, M.; Lundin, M.; Lundin, J.; Tanner, M.; Harkonen, P.; Joensuu, H.; Isola, J.; Elenius, K. Cleavable ERBB4 isoform in estrogen receptor-regulated growth of breast cancer cells. Cancer Res. 2005, 65, 1384–1393. [CrossRef] [PubMed]
20. Ferretti, E.; Di Marcotullio, L.; Gessi, M.; Mattei, T.; Greco, A.; Po, A.; De Smaele, E.; Giangaspero, F.; Riccardi, R.; Di Rocco, C.; et al. Alternative splicing of the ERBB-4 cytoplasmic domain and its regulation by hedgehog signaling identify distinct medulloblastoma subsets. Oncogene 2006, 25, 7267–7273. [CrossRef] [PubMed]
21. Sartor, C.I.; Zhou, H.; Kozlowska, E.; Guttridge, K.; Kawata, E.; Caskey, L.; Harrelson, J.; Hynes, N.; Ethier, S.; Calvo, B.; et al. Her4 mediates ligand-dependent antiproliferative and differentiation responses in human breast cancer cells. Mol. Cell. Biol. 2001, 21, 4265–4275. [CrossRef] [PubMed]
22. Naresh, A.; Long, W.; Vidal, G.A.; Wimley, W.C.; Marrero, L.; Sartor, C.I.; Tovey, S.; Cooke, T.G.; Bartlett, J.M.; Jones, F.E. The ERBB4/HER4 intracellular domain 4ICD is a BH3-only protein promoting apoptosis of breast cancer cells. Cancer Res. 2006, 66, 6412–6420. [CrossRef] [PubMed]
23. Sundvall, M.; Veikkolainen, V.; Kurppa, K.; Salah, Z.; Tvorogov, D.; van Zoelen, E.J.; Aqeilan, R.; Elenius, K. Cell death or survival promoted by alternative isoforms of ERBB4. Mol. Biol. Cell 2010, 21, 4275–4286. [CrossRef] [PubMed]
24. Maatta, J.A.; Sundvall, M.; Junttila, T.T.; Peri, L.; Laine, V.J.; Isola, J.; Egeblad, M.; Elenius, K. Proteolytic cleavage and phosphorylation of a tumor-associated ERBB4 isoform promote ligand-independent survival and cancer cell growth. Mol. Biol. Cell 2006, 17, 67–79. [CrossRef] [PubMed]
25. Tal-Or, P.; Erlich, S.; Porat-Shliom, N.; Goldshmit, Y.; Ben-Baruch, G.; Shaharabani, E.; Kloog, Y.; Pinkas-Kramarski, R. Ligand-independent regulation of ERBB4 receptor phosphorylation by activated ras. J. Cell. Biochem. 2006, 98, 1482–1494. [CrossRef] [PubMed]
26. Zeng, F.; Zhang, M.Z.; Singh, A.B.; Zent, R.; Harris, R.C. ERBB4 isoforms selectively regulate growth factor induced madin-darby canine kidney cell tubulogenesis. Mol. Biol. Cell 2007, 18, 4446–4456. [CrossRef] [PubMed]
27. Sundvall, M.; Peri, L.; Maatta, J.A.; Tvorogov, D.; Paatero, I.; Savisalo, M.; Silvennoinen, O.; Yarden, Y.; Elenius, K. Differential nuclear localization and kinase activity of alternative ERBB4 intracellular domains. Oncogene 2007, 26, 6905–6914. [CrossRef] [PubMed]
28. Prickett, T.D.; Agrawal, N.S.; Wei, X.; Yates, K.E.; Lin, J.C.; Wunderlich, J.R.; Cronin, J.C.; Cruz, P.; Rosenberg, S.A.; Samuels, Y. Analysis of the tyrosine kinome in melanoma reveals recurrent mutations in ERBB4. Nat. Genet. 2009, 41, 1127–1132. [CrossRef] [PubMed]
29. Yoshimoto, K.; Ma, X.; Guan, Y.; Mizoguchi, M.; Nakamizo, A.; Amano, T.; Hata, N.; Kuga, D.; Sasaki, T. Expression of stem cell marker and receptor kinase genes in glioblastoma tissue quantified by real-time RT-PCR. Brain Tumor Pathol. 2011, 28, 291–296. [CrossRef] [PubMed]
30. Veikkolainen, V.; Vaparanta, K.; Halkilahti, K.; Iljin, K.; Sundvall, M.; Elenius, K. Function of ERBB4 is determined by alternative splicing. Cell Cycle 2011, 10, 2647–2657. [CrossRef] [PubMed]
31. Elenius, K.; Choi, C.J.; Paul, S.; Santiestevan, E.; Nishi, E.; Klagsbrun, M. Characterization of a naturally occurring ERBB4 isoform that does not bind or activate phosphatidyl inositol 3-kinase. Oncogene 1999, 18, 2607–2615. [CrossRef] [PubMed]
32. Haas-Kogan, D.A.; Prados, M.D.; Tihan, T.; Eberhard, D.A.; Jelluma, N.; Arvold, N.D.; Baumber, R.; Lamborn, K.R.; Kapadia, A.; Malec, M.; et al. Epidermal growth factor receptor, protein kinase B/Akt, and glioma response to erlotinib. J. Natl. Cancer Inst. 2005, 97, 880–887. [CrossRef] [PubMed]
33. Liu, T.F.; Tatter, S.B.; Willingham, M.C.; Yang, M.; Hu, J.J.; Frankel, A.E. Growth factor receptor expression varies among high-grade gliomas and normal brain: Epidermal growth factor receptor has excellent properties for interstitial fusion protein therapy. Mol. Cancer Ther. 2003, 2, 783–787. [PubMed]
34. Taylor, T.E.; Furnari, F.B.; Cavenee, W.K. Targeting EGFR for treatment of glioblastoma: Molecular basis to overcome resistance. Curr. Cancer Drug Targets 2012, 12, 197–209. [CrossRef] [PubMed]
35. Koziolek, E.J.; Donoghue, J.F.; Bentley, J.D.; Lovrecz, G.; Dolezal, O.; Ward, C.W.; Rothacker, J.; Nice, E.C.; Burgess, A.W.; Hafner, M.; et al. A high-affinity ERBB4fc fusion protein is a potent antagonist of heregulin-mediated receptor activation. Growth Factors 2012, 30, 310–319. [CrossRef] [PubMed]
36. Muraoka-Cook, R.S.; Sandahl, M.A.; Strunk, K.E.; Miraglia, L.C.; Husted, C.; Hunter, D.M.; Elenius, K.; Chodosh, L.A.; Earp, H.S., III. ERBB4 splice variants CYT1 and CYT2 differ by 16 amino acids and exert opposing effects on the mammary epithelium in vivo. Mol. Cell. Biol. 2009, 29, 4935–4948. [CrossRef] [PubMed]
37. Kainulainen, V.; Sundvall, M.; Maatta, J.A.; Santiestevan, E.; Klagsbrun, M.; Elenius, K. A natural ERBB4 isoform that does not activate phosphoinositide 3-kinase mediates proliferation but not survival or chemotaxis. J. Biol. Chem. 2000, 275, 8641–8649. [CrossRef] [PubMed]
38. Schuchardt, B.J.; Bhat, V.; Mikles, D.C.; McDonald, C.B.; Sudol, M.; Farooq, A. Molecular basis of the binding of yap transcriptional regulator to the ERBB4 receptor tyrosine kinase. Biochimie 2014, 101, 192–202. [CrossRef] [PubMed]
39. Sundvall, M.; Korhonen, A.; Paatero, I.; Gaudio, E.; Melino, G.; Croce, C.M.; Aqeilan, R.I.; Elenius, K. Isoform-specific monoubiquitination, endocytosis, and degradation of alternatively spliced ERBB4 isoforms. Proc. Natl. Acad. Sci. USA 2008, 105, 4162–4167. [CrossRef] [PubMed]
40. Zeng, F.; Xu, J.; Harris, R.C. NEDD4 mediates ERBB4 JM-a/CYT-1 ICD ubiquitination and degradation in MDCK II cells. FASEB J. 2009, 23, 1935–1945. [CrossRef] [PubMed]
41. Kiuchi, T.; Ortiz-Zapater, E.; Monypenny, J.; Matthews, D.R.; Nguyen, L.K.; Barbeau, J.; Coban, O.; Lawler, K.; Burford, B.; Rolfe, D.J.; et al. The ERBB4 CYT2 variant protects EGFR from ligand-induced degradation to enhance cancer cell motility. Sci. Signal. 2014, 7, ra78. [CrossRef] [PubMed]
42. Verhaak, R.G.; Hoadley, K.A.; Purdom, E.; Wang, V.; Qi, Y.; Wilkerson, M.D.; Miller, C.R.; Ding, L.; Golub, T.; Mesirov, J.P.; et al. Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1. Cancer Cell 2010, 17, 98–110. [CrossRef] [PubMed]
43. Peereboom, D.M.; Shepard, D.R.; Ahluwalia, M.S.; Brewer, C.J.; Agarwal, N.; Stevens, G.H.; Suh, J.H.; Toms, S.A.; Vogelbaum, M.A.; Weil, R.J.; et al. Phase II trial of erlotinib with temozolomide and radiation in patients with newly diagnosed glioblastoma multiforme. J. Neuro-Oncol. 2010, 98, 93–99. [CrossRef] [PubMed]
44. Raizer, J.J.; Abrey, L.E.; Lassman, A.B.; Chang, S.M.; Lamborn, K.R.; Kuhn, J.G.; Yung, W.K.; Gilbert, M.R.; Aldape, K.A.; Wen, P.Y.; et al. A phase ii trial of erlotinib in patients with recurrent malignant gliomas and nonprogressive glioblastoma multiforme postradiation therapy. Neuro-Oncology 2010, 12, 95–103. [CrossRef] [PubMed]
45. Lievre, A.; Bachet, J.B.; Le Corre, D.; Boige, V.; Landi, B.; Emile, J.F.; Cote, J.F.; Tomasic, G.; Penna, C.; Ducreux, M.; et al. KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer. Cancer Res. 2006, 66, 3992–3995. [CrossRef] [PubMed]
46. Pillay, V.; Allaf, L.; Wilding, A.L.; Donoghue, J.F.; Court, N.W.; Greenall, S.A.; Scott, A.M.; Johns, T.G. The plasticity of oncogene addiction: Implications for targeted therapies directed to receptor tyrosine kinases. Neoplasia 2009, 11, 448–458. [CrossRef] [PubMed]
47. Mishima, K.; Higashiyama, S.; Asai, A.; Yamaoka, K.; Nagashima, Y.; Taniguchi, N.; Kitanaka, C.; Kirino, T.; Kuchino, Y. Heparin-binding epidermal growth factor-like growth factor stimulates mitogenic signaling and is highly expressed in human malignant gliomas. Acta Neuropathol. 1998, 96, 322–328. [CrossRef] [PubMed]
48. Russell, K.S.; Stern, D.F.; Polverini, P.J.; Bender, J.R. Neuregulin activation of ERBB receptors in vascular endothelium leads to angiogenesis. Am. J. Physiol. 1999, 277, H2205–H2211. [CrossRef] [PubMed]
49. Morgenstern, J.P.; Land, H. Advanced mammalian gene transfer: High titre retroviral vectors with multiple drug selection markers and a complementary helper-free packaging cell line. Nucleic Acids Res. 1990, 18, 3587–3596. [CrossRef] [PubMed]
50. Wang, R.; Chadalavada, K.; Wilshire, J.; Kowalik, U.; Hovinga, K.E.; Geber, A.; Fligelman, B.; Leversha, M.; Brennan, C.; Tabar, V. Glioblastoma stem-like cells give rise to tumour endothelium. Nature 2010, 468, 829–833. [CrossRef] [PubMed]
51. Poller, B.; Gutmann, H.; Krahenbuhl, S.; Weksler, B.; Romero, I.; Couraud, P.O.; Tuffin, G.; Drewe, J.; Huwyler, J. The human brain endothelial cell line hCMEC/D3 as a human blood-brain barrier model for drug transport studies. J. Neurochem. 2008, 107, 1358–1368. [CrossRef] [PubMed]